董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert A. Bradway | 男 | Chairman of the Board, Chief Executive Officer,President and Director | 62 | 2442.85万美元 | 138.64 | 2025-05-23 |
| Charles M. Holley, Jr. | 男 | Director | 68 | 39.01万美元 | 0.13 | 2025-05-23 |
| Wanda M. Austin | 女 | Director | 70 | 37.02万美元 | 0.65 | 2025-05-23 |
| Brian J. Druker | 男 | Director | 69 | 37.24万美元 | 0.21 | 2025-05-23 |
| Amy E. Miles | 女 | Director | 58 | 36.01万美元 | 0.04 | 2025-05-23 |
| Mary E. Klotman | 女 | Director | 71 | 30.17万美元 | 0.07 | 2025-05-23 |
| Robert A. Eckert | 男 | Lead Independent Director | 70 | 45.01万美元 | 0.70 | 2025-05-23 |
| Ellen J. Kullman | 女 | Director | 69 | 38.17万美元 | 0.04 | 2025-05-23 |
| S. Omar Ishrak | 男 | Director | 69 | 38.23万美元 | 0.09 | 2025-05-23 |
| Greg C. Garland | 男 | Director | 67 | 40.01万美元 | 1.24 | 2025-05-23 |
| Tyler E. Jacks | 男 | Director | 64 | 36.01万美元 | 0.34 | 2025-05-23 |
| Michael V. Drake | 男 | Director | 74 | 38.01万美元 | 未持股 | 2025-05-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert A. Bradway | 男 | Chairman of the Board, Chief Executive Officer,President and Director | 62 | 2442.85万美元 | 138.64 | 2025-05-23 |
| James Bradner | 男 | Executive Vice President, Research and Development | 52 | 1491.44万美元 | 未持股 | 2025-05-23 |
| Esteban Santos | 男 | Executive Vice President, Operations | 57 | 720.58万美元 | 未持股 | 2025-05-23 |
| Murdo Gordon | 男 | Executive Vice President, Global Commercial Operations | 58 | 847.35万美元 | 17.99 | 2025-05-23 |
| Peter H. Griffith | 男 | Executive Vice President and Chief Financial Officer | 66 | 780.68万美元 | 12.38 | 2025-05-23 |
| David M. Reese | 男 | Executive Vice President and Chief Technology Officer | 62 | 812.68万美元 | 18.46 | 2025-05-23 |
| Nancy A. Grygiel | 女 | Senior Vice President and Chief Compliance Officer | 57 | 未披露 | 未持股 | 2025-05-23 |
| Rachna Khosla | 女 | Senior Vice President, Business Development | 52 | 未披露 | 未持股 | 2025-05-23 |
| Derek Miller | 男 | Senior Vice President, Human Resources | 52 | 未披露 | 未持股 | 2025-05-23 |
| Matthew C. Busch | 男 | Vice President, Finance and Chief Accounting Officer | 51 | 未披露 | 未持股 | 2025-05-23 |
| Jonathan P. Graham | 男 | Executive Vice President and General Counsel and Secretary | 64 | 724.00万美元 | 未持股 | 2025-05-23 |
董事简历
中英对照 | 中文 | 英文- Robert A. Bradway
-
Robert A. Bradway自2011年以来一直担任安进公司（Amgen Inc.）的董事，自2013年起担任董事会主席。自2010年起，Bradway先生担任安进公司的总裁，并于2012年起担任首席执行官。从2010年至2012年，Bradway先生担任安进公司的首席运营官。他于2006年加入安进公司，担任运营策略副总裁，并在2007年至2010年期间担任执行副总裁及首席财务官。在加入安进公司之前，他在伦敦摩根士丹利银行担任董事总经理，自2001年起负责该公司在欧洲的银行业务和公司融资活动。自2016年起，Bradway先生一直担任波音公司的董事，并担任财务委员会主席及治理与公共政策委员会的成员。他自2014年以来一直在南加州大学董事会的信任委员会中任职。Bradway先生拥有安普华兹学院的生物学学士学位和哈佛商学院工商管理硕士学位。
Robert A. Bradway,has served as director since 2011 and Chairman of the Board since 2013. Mr. Bradway has been President since 2010 and Chief Executive Officer since 2012. From 2010 to 2012, Mr. Bradway served as Chief Operating Officer. Mr. Bradway joined Amgen in 2006 as Vice President, Operations Strategy and served as Executive Vice President and Chief Financial Officer from 2007 to 2010. Prior to joining Amgen, he was a Managing Director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm's banking department and corporate finance activities in Europe.Mr. Bradway has been a director of The Boeing Company, an aerospace company and manufacturer of commercial airplanes and defense, space and securities systems, since 2016, serving as the Chair of the Governance and Public Policy Committee and a member of the Compensation Committee. He previously served as the Chair of the Finance Committee of Boeing from 2021 to 2024. Mr. Bradway has served on the board of trustees of USC since 2014. Mr. Bradway holds a bachelor's degree in biology from Amherst College and a master's degree in business administration from Harvard Business School. - Robert A. Bradway自2011年以来一直担任安进公司（Amgen Inc.）的董事，自2013年起担任董事会主席。自2010年起，Bradway先生担任安进公司的总裁，并于2012年起担任首席执行官。从2010年至2012年，Bradway先生担任安进公司的首席运营官。他于2006年加入安进公司，担任运营策略副总裁，并在2007年至2010年期间担任执行副总裁及首席财务官。在加入安进公司之前，他在伦敦摩根士丹利银行担任董事总经理，自2001年起负责该公司在欧洲的银行业务和公司融资活动。自2016年起，Bradway先生一直担任波音公司的董事，并担任财务委员会主席及治理与公共政策委员会的成员。他自2014年以来一直在南加州大学董事会的信任委员会中任职。Bradway先生拥有安普华兹学院的生物学学士学位和哈佛商学院工商管理硕士学位。
- Robert A. Bradway,has served as director since 2011 and Chairman of the Board since 2013. Mr. Bradway has been President since 2010 and Chief Executive Officer since 2012. From 2010 to 2012, Mr. Bradway served as Chief Operating Officer. Mr. Bradway joined Amgen in 2006 as Vice President, Operations Strategy and served as Executive Vice President and Chief Financial Officer from 2007 to 2010. Prior to joining Amgen, he was a Managing Director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm's banking department and corporate finance activities in Europe.Mr. Bradway has been a director of The Boeing Company, an aerospace company and manufacturer of commercial airplanes and defense, space and securities systems, since 2016, serving as the Chair of the Governance and Public Policy Committee and a member of the Compensation Committee. He previously served as the Chair of the Finance Committee of Boeing from 2021 to 2024. Mr. Bradway has served on the board of trustees of USC since 2014. Mr. Bradway holds a bachelor's degree in biology from Amherst College and a master's degree in business administration from Harvard Business School.
- Charles M. Holley, Jr.
-
Charles M. Holley, Jr.是Wal-Mart Stores，Inc.（沃尔玛）的前任执行副总裁兼首席财务官，他于2010年至2015年在沃尔玛任职，并于2016年1月担任执行副总裁。在此之前，Holley先生曾于2007年至2010年担任沃尔玛执行副总裁、财务和财务主管。2005年至2006年，他担任沃尔玛高级副总裁，在此之前，他于2003年至2005年担任高级副总裁兼财务总监。从1994年到2002年，Holley先生在沃尔玛国际公司担任过各种职务。在此之前，Holley先生曾在Tandy Corporation担任过多个职务。他在安永会计师事务所工作了十多年。Holley先生于2016年至2019年在审计、咨询、税务和咨询服务的私营供应商德勤律师事务所担任美国CFO项目的独立高级顾问。Holley先生自2019年起担任Phillips 66的董事，并在审计和财务委员会以及公共政策和可持续发展委员会任职。Holley先生还自2020年起担任供暖、通风、空调（HVAC）、制冷、消防和安保解决方案提供商Carrier Global Corporation的董事，并担任审计委员会主席和治理委员会成员。Holley先生是得克萨斯大学奥斯汀分校McCombs商学院咨询委员会的终身成员，也是得克萨斯大学校长发展委员会的成员。Holley先生获得了得克萨斯大学奥斯汀分校的本科学位和休斯顿大学的工商管理硕士学位。
Charles M. Holley, Jr.,is the former Executive Vice President and Chief Financial Officer for Wal-Mart Stores, Inc., or Walmart, where he served from 2010 to 2015 and as Executive Vice President in January 2016. Prior to this, Mr. Holley served as Executive Vice President, Finance and Treasurer of Walmart from 2007 to 2010. From 2005 to 2006, he served as Senior Vice President of Walmart and prior to that, as Senior Vice President and Controller from 2003 to 2005. Mr. Holley served various roles in Wal-Mart International from 1994 through 2002. Prior to this, Mr. Holley served in various roles at Tandy Corporation. He spent more than ten years with Ernst & Young LLP. Mr. Holley was an Independent Senior Advisor, U.S. CFO Program, at Deloitte LLP, a privately held provider of audit, consulting, tax, and advisory services, from 2016 to 2019.Mr. Holley has been a director of Phillips 66, since 2019 and serves on the Audit and Finance Committee and the Public Policy and Sustainability Committee. Mr. Holley has also been a director of Carrier Global Corporation, a provider of heating, ventilating, air conditioning (HVAC), refrigeration, fire, and security solutions, since 2020 and chairs the Audit Committee and serves as a member of the Governance Committee. Mr. Holley is a lifetime member of the Advisory Council for the McCombs School of Business at the University of Texas at Austin and a member of the University of Texas Presidents' Development Board. Mr. Holley received an undergraduate degree from the University of Texas at Austin and a master's degree in business administration from the University of Houston. - Charles M. Holley, Jr.是Wal-Mart Stores，Inc.（沃尔玛）的前任执行副总裁兼首席财务官，他于2010年至2015年在沃尔玛任职，并于2016年1月担任执行副总裁。在此之前，Holley先生曾于2007年至2010年担任沃尔玛执行副总裁、财务和财务主管。2005年至2006年，他担任沃尔玛高级副总裁，在此之前，他于2003年至2005年担任高级副总裁兼财务总监。从1994年到2002年，Holley先生在沃尔玛国际公司担任过各种职务。在此之前，Holley先生曾在Tandy Corporation担任过多个职务。他在安永会计师事务所工作了十多年。Holley先生于2016年至2019年在审计、咨询、税务和咨询服务的私营供应商德勤律师事务所担任美国CFO项目的独立高级顾问。Holley先生自2019年起担任Phillips 66的董事，并在审计和财务委员会以及公共政策和可持续发展委员会任职。Holley先生还自2020年起担任供暖、通风、空调（HVAC）、制冷、消防和安保解决方案提供商Carrier Global Corporation的董事，并担任审计委员会主席和治理委员会成员。Holley先生是得克萨斯大学奥斯汀分校McCombs商学院咨询委员会的终身成员，也是得克萨斯大学校长发展委员会的成员。Holley先生获得了得克萨斯大学奥斯汀分校的本科学位和休斯顿大学的工商管理硕士学位。
- Charles M. Holley, Jr.,is the former Executive Vice President and Chief Financial Officer for Wal-Mart Stores, Inc., or Walmart, where he served from 2010 to 2015 and as Executive Vice President in January 2016. Prior to this, Mr. Holley served as Executive Vice President, Finance and Treasurer of Walmart from 2007 to 2010. From 2005 to 2006, he served as Senior Vice President of Walmart and prior to that, as Senior Vice President and Controller from 2003 to 2005. Mr. Holley served various roles in Wal-Mart International from 1994 through 2002. Prior to this, Mr. Holley served in various roles at Tandy Corporation. He spent more than ten years with Ernst & Young LLP. Mr. Holley was an Independent Senior Advisor, U.S. CFO Program, at Deloitte LLP, a privately held provider of audit, consulting, tax, and advisory services, from 2016 to 2019.Mr. Holley has been a director of Phillips 66, since 2019 and serves on the Audit and Finance Committee and the Public Policy and Sustainability Committee. Mr. Holley has also been a director of Carrier Global Corporation, a provider of heating, ventilating, air conditioning (HVAC), refrigeration, fire, and security solutions, since 2020 and chairs the Audit Committee and serves as a member of the Governance Committee. Mr. Holley is a lifetime member of the Advisory Council for the McCombs School of Business at the University of Texas at Austin and a member of the University of Texas Presidents' Development Board. Mr. Holley received an undergraduate degree from the University of Texas at Austin and a master's degree in business administration from the University of Houston.
- Wanda M. Austin
-
Wanda M. Austin，她是the Aerospace Corporation的退休总裁兼首席执行官，该公司是美国国家安全空间计划的领先建筑师，她在该公司任职（2008年至2016年退休）。从2004年到2007年，她担任The Aerospace Corporation的National Systems Group的高级副总裁。她于1979年加入The Aerospace Corporation，从1979年到2004年担任多个职位。Austin博士于2018年至2019年担任南加州大学（USC）的临时校长，并自2007年以来担任USC维特比工程学院的兼职研究教授。她是MakingSpace， Inc.的联合创始人，在那里她担任科学、技术、工程和数学（STEM）教育的励志演说家。自2024年2月以来，她一直担任Apple Inc.（个人电脑、移动和通信设备的制造商和销售商）的董事，并在其审计和财务委员会任职。Austin博士自2016年起担任Chevron Corporation（石油、勘探、生产和炼油公司）的董事，自2022年起担任首席独立董事，担任董事会提名和治理委员会主席以及管理薪酬委员会成员。从2019年到2023年，她担任Virgin Galactic Holdings， Inc.（一家商业太空飞行公司）的董事，担任薪酬委员会主席和安全委员会成员。Austin博士是USC的终身受托人，从2010年到2021年担任投票受托人，此前曾担任美国国家地理学会和太空基金会的董事会成员。她持有Franklin & Marshall College的本科学位、Pittsburgh大学的硕士学位和USC的博士学位。她是美国国家工程院院士。
Wanda M. Austin,is the retired President and Chief Executive Officer of The Aerospace Corporation, a leading architect of the United States' national security space programs, where she served from 2008 until her retirement in 2016. From 2004 to 2007, Dr. Austin was Senior Vice President, National Systems Group of The Aerospace Corporation. Dr. Austin joined The Aerospace Corporation in 1979 and served in various positions from 1979 until 2004. Dr. Austin was the Interim President of the University of Southern California, or USC, from 2018 to 2019 and has served as an Adjunct Research Professor at USC's Viterbi School of Engineering since 2007. She is the co-founder of MakingSpace, Inc., where she serves as a motivational speaker on science, technology, engineering, and mathematics (STEM) education. Dr. Austin has been a director of Apple Inc., a manufacturer and seller of, among other things, personal computers and mobile and communication devices, since February 2024, serving on its Audit and Finance Committee. Dr. Austin has been a director of Chevron Corporation, a petroleum, exploration, production and refining company, since 2016 and lead independent director since 2022, serving as the Chair of the Board Nominating and Governance Committee and a member of the Management Compensation Committee. Dr. Austin served as a director of Virgin Galactic Holdings, Inc., a commercial space flight company, from 2019 until 2023, serving as the Chair of the Compensation Committee and a member of the Safety Committee. Dr. Austin is a life trustee of USC, having served as a voting trustee from 2010 to 2021, and previously served on the boards of directors of the National Geographic Society and the Space Foundation. Dr. Austin received an undergraduate degree from Franklin & Marshall College, a master's degree from the University of Pittsburgh, and a doctorate from USC. She is a member of the National Academy of Engineering. - Wanda M. Austin，她是the Aerospace Corporation的退休总裁兼首席执行官，该公司是美国国家安全空间计划的领先建筑师，她在该公司任职（2008年至2016年退休）。从2004年到2007年，她担任The Aerospace Corporation的National Systems Group的高级副总裁。她于1979年加入The Aerospace Corporation，从1979年到2004年担任多个职位。Austin博士于2018年至2019年担任南加州大学（USC）的临时校长，并自2007年以来担任USC维特比工程学院的兼职研究教授。她是MakingSpace， Inc.的联合创始人，在那里她担任科学、技术、工程和数学（STEM）教育的励志演说家。自2024年2月以来，她一直担任Apple Inc.（个人电脑、移动和通信设备的制造商和销售商）的董事，并在其审计和财务委员会任职。Austin博士自2016年起担任Chevron Corporation（石油、勘探、生产和炼油公司）的董事，自2022年起担任首席独立董事，担任董事会提名和治理委员会主席以及管理薪酬委员会成员。从2019年到2023年，她担任Virgin Galactic Holdings， Inc.（一家商业太空飞行公司）的董事，担任薪酬委员会主席和安全委员会成员。Austin博士是USC的终身受托人，从2010年到2021年担任投票受托人，此前曾担任美国国家地理学会和太空基金会的董事会成员。她持有Franklin & Marshall College的本科学位、Pittsburgh大学的硕士学位和USC的博士学位。她是美国国家工程院院士。
- Wanda M. Austin,is the retired President and Chief Executive Officer of The Aerospace Corporation, a leading architect of the United States' national security space programs, where she served from 2008 until her retirement in 2016. From 2004 to 2007, Dr. Austin was Senior Vice President, National Systems Group of The Aerospace Corporation. Dr. Austin joined The Aerospace Corporation in 1979 and served in various positions from 1979 until 2004. Dr. Austin was the Interim President of the University of Southern California, or USC, from 2018 to 2019 and has served as an Adjunct Research Professor at USC's Viterbi School of Engineering since 2007. She is the co-founder of MakingSpace, Inc., where she serves as a motivational speaker on science, technology, engineering, and mathematics (STEM) education. Dr. Austin has been a director of Apple Inc., a manufacturer and seller of, among other things, personal computers and mobile and communication devices, since February 2024, serving on its Audit and Finance Committee. Dr. Austin has been a director of Chevron Corporation, a petroleum, exploration, production and refining company, since 2016 and lead independent director since 2022, serving as the Chair of the Board Nominating and Governance Committee and a member of the Management Compensation Committee. Dr. Austin served as a director of Virgin Galactic Holdings, Inc., a commercial space flight company, from 2019 until 2023, serving as the Chair of the Compensation Committee and a member of the Safety Committee. Dr. Austin is a life trustee of USC, having served as a voting trustee from 2010 to 2021, and previously served on the boards of directors of the National Geographic Society and the Space Foundation. Dr. Austin received an undergraduate degree from Franklin & Marshall College, a master's degree from the University of Pittsburgh, and a doctorate from USC. She is a member of the National Academy of Engineering.
- Brian J. Druker
-
Brian J. Druker于1993加入俄勒冈健康与科学大学OHSU，目前是内科医师和医学教授。Druker博士自2007年起担任OHSU Knight癌症研究所所长，2010年起担任OHSU医学院肿瘤学副院长，2001年起担任OHSU白血病研究的JELD-WEN主席。2002年至2019年，他在非营利医学研究机构Howard Hughes医学研究所任研究员。德鲁克自2020年12月起担任生物制药公司Vincerx Pharma，Inc.的董事，并在提名和公司治理委员会任职。Druker博士自2013年起在生物技术公司Aptose Biosciences Inc.的科学咨询委员会任职。2016年至2019年，Druker博士在生物技术公司Grail，Inc.的科学咨询委员会任职。2011年，他成立了生物制药公司Blueprint Medicines Corporation，仍然是Blueprint Medicines Corporation的科学顾问。2006年，他创立了一家私人控股的分子诊断公司MolecularMD，MolecularMD于2019年被ICON plc收购。Druker获得了许多奖项，包括2009年的Lasker DeBakey临床研究奖、2012年的日本医疗保健和医疗技术奖、2013年的奥尔巴尼医疗中心奖和2019年的Sjberg奖，表彰其在STI571格列卫的开发方面的有影响力的工作用于治疗慢性粒细胞白血病。他于2012被选入美国国家科学院，2007被选为国家医学院。Druker博士同时获得了圣地亚哥加利福尼亚大学的本科学位和博士学位。
Brian J. Druker,was the director of the Oregon Health & Science University, or OHSU, Knight Cancer Institute from 2007 to 2024. Dr. Druker joined OHSU in 1993 and is currently a physician-scientist and professor of medicine. Dr. Druker served as an associate dean for oncology of the OHSU School of Medicine from 2010 to 2024, and the JELD-WEN chair of leukemia research at OHSU since 2001. He was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, from 2002 to 2019.Dr. Druker has been a director of Vincerx Pharma, Inc., a biopharmaceutical company, since December 2020, and serves on its Nominating and Corporate Governance Committee. Dr. Druker has been a member of the scientific advisory board of Aptose Biosciences Inc., a biotechnology company, since 2013. Dr. Druker has been a consultant to GRAIL, Inc. (formerly known as GRAIL, LLC), a biotechnology company, since 2021, and served on its scientific advisory board, from 2016 to 2019. In 2011, he founded Blueprint Medicines Corporation, a biopharmaceutical company, and remains as a scientific advisor to this company. In 2006, he founded MolecularMD, a privately held molecular diagnostics company that was acquired by ICON plc in 2019. Dr. Druker has been a member of the board of directors of the Burroughs Wellcome Fund since 2018, an independent, private foundation supporting research and other scientific and education activities.Dr. Druker has received numerous awards, including the Lasker-DeBakey Clinical Research Award in 2009, the Japan Prize in Healthcare and Medical Technology in 2012, the Albany Medical Center Prize in 2013, and the Sjberg Prize in 2019, for influential work in the development of STI571 (Gleevec) for the treatment of chronic myeloid leukemia. He was elected to the National Academy of Sciences in 2012 as well as the National Academy of Medicine in 2007. Dr. Druker received both an undergraduate degree and his medical doctorate from the University of California, San Diego. - Brian J. Druker于1993加入俄勒冈健康与科学大学OHSU，目前是内科医师和医学教授。Druker博士自2007年起担任OHSU Knight癌症研究所所长，2010年起担任OHSU医学院肿瘤学副院长，2001年起担任OHSU白血病研究的JELD-WEN主席。2002年至2019年，他在非营利医学研究机构Howard Hughes医学研究所任研究员。德鲁克自2020年12月起担任生物制药公司Vincerx Pharma，Inc.的董事，并在提名和公司治理委员会任职。Druker博士自2013年起在生物技术公司Aptose Biosciences Inc.的科学咨询委员会任职。2016年至2019年，Druker博士在生物技术公司Grail，Inc.的科学咨询委员会任职。2011年，他成立了生物制药公司Blueprint Medicines Corporation，仍然是Blueprint Medicines Corporation的科学顾问。2006年，他创立了一家私人控股的分子诊断公司MolecularMD，MolecularMD于2019年被ICON plc收购。Druker获得了许多奖项，包括2009年的Lasker DeBakey临床研究奖、2012年的日本医疗保健和医疗技术奖、2013年的奥尔巴尼医疗中心奖和2019年的Sjberg奖，表彰其在STI571格列卫的开发方面的有影响力的工作用于治疗慢性粒细胞白血病。他于2012被选入美国国家科学院，2007被选为国家医学院。Druker博士同时获得了圣地亚哥加利福尼亚大学的本科学位和博士学位。
- Brian J. Druker,was the director of the Oregon Health & Science University, or OHSU, Knight Cancer Institute from 2007 to 2024. Dr. Druker joined OHSU in 1993 and is currently a physician-scientist and professor of medicine. Dr. Druker served as an associate dean for oncology of the OHSU School of Medicine from 2010 to 2024, and the JELD-WEN chair of leukemia research at OHSU since 2001. He was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, from 2002 to 2019.Dr. Druker has been a director of Vincerx Pharma, Inc., a biopharmaceutical company, since December 2020, and serves on its Nominating and Corporate Governance Committee. Dr. Druker has been a member of the scientific advisory board of Aptose Biosciences Inc., a biotechnology company, since 2013. Dr. Druker has been a consultant to GRAIL, Inc. (formerly known as GRAIL, LLC), a biotechnology company, since 2021, and served on its scientific advisory board, from 2016 to 2019. In 2011, he founded Blueprint Medicines Corporation, a biopharmaceutical company, and remains as a scientific advisor to this company. In 2006, he founded MolecularMD, a privately held molecular diagnostics company that was acquired by ICON plc in 2019. Dr. Druker has been a member of the board of directors of the Burroughs Wellcome Fund since 2018, an independent, private foundation supporting research and other scientific and education activities.Dr. Druker has received numerous awards, including the Lasker-DeBakey Clinical Research Award in 2009, the Japan Prize in Healthcare and Medical Technology in 2012, the Albany Medical Center Prize in 2013, and the Sjberg Prize in 2019, for influential work in the development of STI571 (Gleevec) for the treatment of chronic myeloid leukemia. He was elected to the National Academy of Sciences in 2012 as well as the National Academy of Medicine in 2007. Dr. Druker received both an undergraduate degree and his medical doctorate from the University of California, San Diego.
- Amy E. Miles
-
Amy E. Miles自2020年7月起担任安进公司董事。迈尔斯首先被董事会主席确定为治理和提名委员会的潜在董事候选人。Miles女士曾担任Regal Entertainment Group，Inc.或Regal Entertainment（一家领先的戏剧展览公司）的首席执行官和董事，2009年至2018年担任首席执行官和董事职位，2015年至2018年担任董事会主席。2002年至2009年，Miles女士担任执行副总裁，富豪娱乐首席财务官兼财务主管。2009年至2018年，迈尔斯女士还担任富豪影院公司（Regal Cinemas，Inc.）的首席执行官，2000年至2009年，她还担任Regal Cinemas，Inc.的执行副总裁、首席财务官和财务主管。1999年，迈尔斯女士加入富豪影院，担任财务高级副总裁。此前，迈尔斯曾任职于德勤会计师事务所（Deloitte&Touche，LLP）和普华永道会计师事务所（PricewaterhouseCoopers LLP.Ms）。迈尔斯自2014年起担任运输公司诺福克南方公司（Norfolk Southern Corporation）董事，担任执行委员会、治理和提名委员会成员，并担任审计委员会主席。迈尔斯自2020年4月起担任服装零售公司Gap，Inc.的董事，并在审计和财务委员会任职。2011年至2015年，迈尔斯女士曾任电影广告公司National CineMedia，Inc.的董事。2014年至2016年，她曾任广播、数字媒体、娱乐和数字营销解决方案公司Townsquare Media，Inc.的董事。自2019以来，迈尔斯一直是一家私人娱乐和场馆管理公司ASM Global的董事。迈尔斯女士任职于田纳西大学董事会和田纳西州东部的男孩女孩俱乐部。
Amy E. Miles,was the Chief Executive Officer and a director of Regal Entertainment Group, Inc., or Regal Entertainment, a leading theatre exhibition company, having held these positions from 2009 through 2018, and its Chair of the Board from 2015 to 2018. From 2002 to 2009, Ms. Miles served as Executive Vice President, Chief Financial Officer and Treasurer of Regal Entertainment. Ms. Miles also served as Chief Executive Officer of Regal Cinemas, Inc., or Regal Cinemas, from 2009 to 2018, and its Executive Vice President, Chief Financial Officer and Treasurer from 2000 to 2009. Ms. Miles joined Regal Cinemas in 1999 as Senior Vice President of Finance. Previously, Ms. Miles was with Deloitte & Touche, LLP and PricewaterhouseCoopers LLP.Ms. Miles has been a director of The Gap, Inc., an apparel retail company, since 2020, and chairs the Audit and Finance Committee and is a member of the Governance and Sustainability Committee. Ms. Miles has also been a director of Carrier Global Corporation since January 2025 and serves as a member of the Audit and Governance Committees. Ms. Miles was a director of Norfolk Southern Corporation, a transportation company, from 2014 to 2024 and non-executive Chair of the Board and Chair of the Executive Committee from 2022 to 2024. Ms. Miles was a director of National CineMedia, Inc., a cinema advertising company, from 2011 to 2015. She was a director of Townsquare Media, Inc., a radio, digital media, entertainment, and digital marketing solutions company, from 2014 until 2016. Ms. Miles serves on the board of trustees of the Boys and Girls Club of Eastern Tennessee. Ms. Miles received an undergraduate degree from the University of Tennessee. - Amy E. Miles自2020年7月起担任安进公司董事。迈尔斯首先被董事会主席确定为治理和提名委员会的潜在董事候选人。Miles女士曾担任Regal Entertainment Group，Inc.或Regal Entertainment（一家领先的戏剧展览公司）的首席执行官和董事，2009年至2018年担任首席执行官和董事职位，2015年至2018年担任董事会主席。2002年至2009年，Miles女士担任执行副总裁，富豪娱乐首席财务官兼财务主管。2009年至2018年，迈尔斯女士还担任富豪影院公司（Regal Cinemas，Inc.）的首席执行官，2000年至2009年，她还担任Regal Cinemas，Inc.的执行副总裁、首席财务官和财务主管。1999年，迈尔斯女士加入富豪影院，担任财务高级副总裁。此前，迈尔斯曾任职于德勤会计师事务所（Deloitte&Touche，LLP）和普华永道会计师事务所（PricewaterhouseCoopers LLP.Ms）。迈尔斯自2014年起担任运输公司诺福克南方公司（Norfolk Southern Corporation）董事，担任执行委员会、治理和提名委员会成员，并担任审计委员会主席。迈尔斯自2020年4月起担任服装零售公司Gap，Inc.的董事，并在审计和财务委员会任职。2011年至2015年，迈尔斯女士曾任电影广告公司National CineMedia，Inc.的董事。2014年至2016年，她曾任广播、数字媒体、娱乐和数字营销解决方案公司Townsquare Media，Inc.的董事。自2019以来，迈尔斯一直是一家私人娱乐和场馆管理公司ASM Global的董事。迈尔斯女士任职于田纳西大学董事会和田纳西州东部的男孩女孩俱乐部。
- Amy E. Miles,was the Chief Executive Officer and a director of Regal Entertainment Group, Inc., or Regal Entertainment, a leading theatre exhibition company, having held these positions from 2009 through 2018, and its Chair of the Board from 2015 to 2018. From 2002 to 2009, Ms. Miles served as Executive Vice President, Chief Financial Officer and Treasurer of Regal Entertainment. Ms. Miles also served as Chief Executive Officer of Regal Cinemas, Inc., or Regal Cinemas, from 2009 to 2018, and its Executive Vice President, Chief Financial Officer and Treasurer from 2000 to 2009. Ms. Miles joined Regal Cinemas in 1999 as Senior Vice President of Finance. Previously, Ms. Miles was with Deloitte & Touche, LLP and PricewaterhouseCoopers LLP.Ms. Miles has been a director of The Gap, Inc., an apparel retail company, since 2020, and chairs the Audit and Finance Committee and is a member of the Governance and Sustainability Committee. Ms. Miles has also been a director of Carrier Global Corporation since January 2025 and serves as a member of the Audit and Governance Committees. Ms. Miles was a director of Norfolk Southern Corporation, a transportation company, from 2014 to 2024 and non-executive Chair of the Board and Chair of the Executive Committee from 2022 to 2024. Ms. Miles was a director of National CineMedia, Inc., a cinema advertising company, from 2011 to 2015. She was a director of Townsquare Media, Inc., a radio, digital media, entertainment, and digital marketing solutions company, from 2014 until 2016. Ms. Miles serves on the board of trustees of the Boys and Girls Club of Eastern Tennessee. Ms. Miles received an undergraduate degree from the University of Tennessee.
- Mary E. Klotman
-
Mary E. Klotman，自2023年起担任杜克大学健康事务执行副总裁，自2017年起担任杜克大学医学院院长，自2020年起担任杜克健康首席学术官。Klotman博士此前曾于2010年至2017年担任杜克大学医学院医学系主任。她曾是西奈山伊坎医学院的Irene and Dr. Arthur M. Fishberg的医学教授，并于1997年至2010年担任感染性疾病司司长。Klotman博士还是西奈山全球健康和新发病原体研究所的联合主任，该项目旨在将基础科学发现转化为新出现和重新出现的传染病的临床治疗方法。Dr.Klotman于2014年入选美国国家医学研究院，2021年入选美国艺术与科学院。Klotman博士获得了杜克大学的本科学位和医学博士学位。
Mary E. Klotman,has been Executive Vice President for Health Affairs of Duke University since 2023, Dean of the Duke University School of Medicine since 2017, and Chief Academic Officer of Duke Health since 2020. Dr. Klotman previously served as chair of the Department of Medicine in the Duke University School of Medicine from 2010 to 2017. She was the Irene and Dr. Arthur M. Fishberg Professor of Medicine at the Mount Sinai School of Medicine and served as chief of the Division of Infectious Diseases from 1997 to 2010. Dr. Klotman was also co-director of Mount Sinai's Global Health and Emerging Pathogens Institute, a program designed to translate basic science discoveries into clinical therapeutics for newly emerging and re-emerging infectious diseases.Dr. Klotman was elected to the National Academy of Medicine in 2014 and the American Academy of Arts and Sciences in 2021. Dr. Klotman received both her undergraduate degree and her medical doctorate from Duke University. - Mary E. Klotman，自2023年起担任杜克大学健康事务执行副总裁，自2017年起担任杜克大学医学院院长，自2020年起担任杜克健康首席学术官。Klotman博士此前曾于2010年至2017年担任杜克大学医学院医学系主任。她曾是西奈山伊坎医学院的Irene and Dr. Arthur M. Fishberg的医学教授，并于1997年至2010年担任感染性疾病司司长。Klotman博士还是西奈山全球健康和新发病原体研究所的联合主任，该项目旨在将基础科学发现转化为新出现和重新出现的传染病的临床治疗方法。Dr.Klotman于2014年入选美国国家医学研究院，2021年入选美国艺术与科学院。Klotman博士获得了杜克大学的本科学位和医学博士学位。
- Mary E. Klotman,has been Executive Vice President for Health Affairs of Duke University since 2023, Dean of the Duke University School of Medicine since 2017, and Chief Academic Officer of Duke Health since 2020. Dr. Klotman previously served as chair of the Department of Medicine in the Duke University School of Medicine from 2010 to 2017. She was the Irene and Dr. Arthur M. Fishberg Professor of Medicine at the Mount Sinai School of Medicine and served as chief of the Division of Infectious Diseases from 1997 to 2010. Dr. Klotman was also co-director of Mount Sinai's Global Health and Emerging Pathogens Institute, a program designed to translate basic science discoveries into clinical therapeutics for newly emerging and re-emerging infectious diseases.Dr. Klotman was elected to the National Academy of Medicine in 2014 and the American Academy of Arts and Sciences in 2021. Dr. Klotman received both her undergraduate degree and her medical doctorate from Duke University.
- Robert A. Eckert
-
Robert A. Eckert，自2020年3月起在优步科技有限公司董事会任职。Eckert先生自2014年以来一直是私募股权公司FFL Partners，LLC的运营合伙人。Eckert先生还是美泰公司的名誉主席，自2013年起担任该职务。他在2000年至2011年期间担任美泰的董事长兼首席执行官，并继续担任其董事长至2012年。他此前在卡夫食品公司工作了23年，1997年至2000年担任总裁兼首席执行官。从1995年到1997年，Eckert先生担任卡夫食品的集团副总裁，从1993年到1995年，他担任卡夫食品的Oscar Mayer食品部门总裁。Eckert先生目前在安进、Levi Strauss & Co.和Quinn公司的董事会任职。此前，他曾于2003年至2023年担任麦当劳公司董事会成员。
Robert A. Eckert,is lead independent director. Mr. Eckert has been an Operating Partner at FFL Partners, LLC (formerly known as Friedman Fleischer & Lowe, LLP), a private equity firm, since 2014. Mr. Eckert was the Chief Executive Officer of Mattel, Inc., a toy design, manufacturing, and marketing company, having held this position from 2000 through 2011, and its Chairman of the Board from 2000 through 2012. He was President and Chief Executive Officer of Kraft Foods Inc., a consumer packaged food and beverage company, from 1997 to 2000, Group Vice President from 1995 to 1997, President of the Oscar Mayer Foods Division from 1993 to 1995 and held various other senior executive and other positions from 1977 to 1992.Mr. Eckert has been a director of Levi Strauss & Co., a jeans and casual wear manufacturer, since 2010 and non-executive Chair of the Board since 2021, serving as the Chair of the Nominating, Governance and Corporate Citizenship Committee and a member of the Compensation and Human Capital Committee. Mr. Eckert also has served as a director of Uber Technologies, Inc., a personal mobility, meal delivery and logistics technology platform, since 2020, serving as the Chair of the Compensation Committee and a member of the Nominating and Governance Committee. Mr. Eckert served as a director of McDonald's Corporation, a company that franchises and operates McDonald's restaurants in the global restaurant industry, from 2003 until 2023, serving as a member of the Public Policy and Strategy Committee and the Governance Committee. He was appointed a director of Eyemart Express Holdings LLC, a privately held eyewear retailer and portfolio company of FFL Partners, LLC, in 2015. Mr. Eckert is on the Global Advisory Board of the Kellogg School of Management at Northwestern University and serves on the Eller College National Board of Advisors at the University of Arizona. Mr. Eckert received an undergraduate degree from the University of Arizona and a master's degree in business administration from the Kellogg School of Management at Northwestern University. - Robert A. Eckert，自2020年3月起在优步科技有限公司董事会任职。Eckert先生自2014年以来一直是私募股权公司FFL Partners，LLC的运营合伙人。Eckert先生还是美泰公司的名誉主席，自2013年起担任该职务。他在2000年至2011年期间担任美泰的董事长兼首席执行官，并继续担任其董事长至2012年。他此前在卡夫食品公司工作了23年，1997年至2000年担任总裁兼首席执行官。从1995年到1997年，Eckert先生担任卡夫食品的集团副总裁，从1993年到1995年，他担任卡夫食品的Oscar Mayer食品部门总裁。Eckert先生目前在安进、Levi Strauss & Co.和Quinn公司的董事会任职。此前，他曾于2003年至2023年担任麦当劳公司董事会成员。
- Robert A. Eckert,is lead independent director. Mr. Eckert has been an Operating Partner at FFL Partners, LLC (formerly known as Friedman Fleischer & Lowe, LLP), a private equity firm, since 2014. Mr. Eckert was the Chief Executive Officer of Mattel, Inc., a toy design, manufacturing, and marketing company, having held this position from 2000 through 2011, and its Chairman of the Board from 2000 through 2012. He was President and Chief Executive Officer of Kraft Foods Inc., a consumer packaged food and beverage company, from 1997 to 2000, Group Vice President from 1995 to 1997, President of the Oscar Mayer Foods Division from 1993 to 1995 and held various other senior executive and other positions from 1977 to 1992.Mr. Eckert has been a director of Levi Strauss & Co., a jeans and casual wear manufacturer, since 2010 and non-executive Chair of the Board since 2021, serving as the Chair of the Nominating, Governance and Corporate Citizenship Committee and a member of the Compensation and Human Capital Committee. Mr. Eckert also has served as a director of Uber Technologies, Inc., a personal mobility, meal delivery and logistics technology platform, since 2020, serving as the Chair of the Compensation Committee and a member of the Nominating and Governance Committee. Mr. Eckert served as a director of McDonald's Corporation, a company that franchises and operates McDonald's restaurants in the global restaurant industry, from 2003 until 2023, serving as a member of the Public Policy and Strategy Committee and the Governance Committee. He was appointed a director of Eyemart Express Holdings LLC, a privately held eyewear retailer and portfolio company of FFL Partners, LLC, in 2015. Mr. Eckert is on the Global Advisory Board of the Kellogg School of Management at Northwestern University and serves on the Eller College National Board of Advisors at the University of Arizona. Mr. Eckert received an undergraduate degree from the University of Arizona and a master's degree in business administration from the Kellogg School of Management at Northwestern University.
- Ellen J. Kullman
-
Ellen J. Kullman，自2022年6月起担任Carbon， Inc. （3D打印公司）的执行主席。她曾担任Carbon， Inc.的总裁兼首席执行官（2019年11月至2022年6月），并自2016年以来担任其董事会成员。2009年1月至2015年10月，她曾担任E. I. du Pont de Nemours and Company（为不同行业提供基础材料和创新产品和服务）的首席执行官；2009年12月至2015年10月，担任杜邦公司主席。她从2008年10月到2008年12月担任杜邦公司总裁，从2006年6月到2008年9月担任杜邦公司执行副总裁。在担任这些职务之前，她曾担任杜邦安全与保护集团副总裁。她曾担任美中贸易全国委员会主席，美国-印度首席执行官论坛成员和商业委员会执行委员会成员。她是美国国家工程院的成员，并共同主持了“改变对话：从研究到行动”委员会。她还担任Amgen公司（人类治疗药物的开发商和制造商）和The Goldman Sachs Group公司（全球投资银行、证券和投资管理公司）的董事。2011年至2020年4月，她担任联合技术公司（建筑系统和航空航天工业的高科技产品和服务提供商）的董事。她是Northwestern University的董事会成员，也是Tufts University School of Engineering的顾问委员会成员。
Ellen J. Kullman,has been the Executive Chair of Carbon, Inc., a 3D printing company, since June 2022. Mrs. Kullman served as President and Chief Executive Officer of Carbon, Inc. from November 2019 to June 2022, and as a member of its board of directors since 2016. Mrs. Kullman previously served as Chief Executive Officer of E. I. du Pont de Nemours and Company, or DuPont, a provider of basic materials and innovative products and services for diverse industries, from January 2009 to October 2015 and as Chair of DuPont from December 2009 to October 2015. She served as President of DuPont from October 2008 to December 2008 and as Executive Vice President of DuPont from June 2006 to September 2008. Before her service in those positions, Mrs. Kullman was Group Vice President-DuPont Safety & Protection.She has served as Chair of the US-China Business Council, a member of the US-India CEO Forum and on the executive committee of the Business Council. She is a member of the National Academy of Engineering and co-chaired their Committee on Changing the Conversation: From Research to Action. She is a member of the board of trustees of Northwestern University and serves on the board of advisors of Tufts University School of Engineering. - Ellen J. Kullman，自2022年6月起担任Carbon， Inc. （3D打印公司）的执行主席。她曾担任Carbon， Inc.的总裁兼首席执行官（2019年11月至2022年6月），并自2016年以来担任其董事会成员。2009年1月至2015年10月，她曾担任E. I. du Pont de Nemours and Company（为不同行业提供基础材料和创新产品和服务）的首席执行官；2009年12月至2015年10月，担任杜邦公司主席。她从2008年10月到2008年12月担任杜邦公司总裁，从2006年6月到2008年9月担任杜邦公司执行副总裁。在担任这些职务之前，她曾担任杜邦安全与保护集团副总裁。她曾担任美中贸易全国委员会主席，美国-印度首席执行官论坛成员和商业委员会执行委员会成员。她是美国国家工程院的成员，并共同主持了“改变对话：从研究到行动”委员会。她还担任Amgen公司（人类治疗药物的开发商和制造商）和The Goldman Sachs Group公司（全球投资银行、证券和投资管理公司）的董事。2011年至2020年4月，她担任联合技术公司（建筑系统和航空航天工业的高科技产品和服务提供商）的董事。她是Northwestern University的董事会成员，也是Tufts University School of Engineering的顾问委员会成员。
- Ellen J. Kullman,has been the Executive Chair of Carbon, Inc., a 3D printing company, since June 2022. Mrs. Kullman served as President and Chief Executive Officer of Carbon, Inc. from November 2019 to June 2022, and as a member of its board of directors since 2016. Mrs. Kullman previously served as Chief Executive Officer of E. I. du Pont de Nemours and Company, or DuPont, a provider of basic materials and innovative products and services for diverse industries, from January 2009 to October 2015 and as Chair of DuPont from December 2009 to October 2015. She served as President of DuPont from October 2008 to December 2008 and as Executive Vice President of DuPont from June 2006 to September 2008. Before her service in those positions, Mrs. Kullman was Group Vice President-DuPont Safety & Protection.She has served as Chair of the US-China Business Council, a member of the US-India CEO Forum and on the executive committee of the Business Council. She is a member of the National Academy of Engineering and co-chaired their Committee on Changing the Conversation: From Research to Action. She is a member of the board of trustees of Northwestern University and serves on the board of advisors of Tufts University School of Engineering.
- S. Omar Ishrak
-
S. Omar Ishrak,Medtronic plc，医疗设备公司，董事长兼首席执行官（2011-2020年退休）。GE医疗保健系统是GE医疗保健部门和综合医疗成像和诊断技术提供商。2009-2011年担任总裁兼首席执行官。其他公共董事会成员，生物制药公司Amgen Inc.，医疗保健公司Allurion Technologies Inc.。
S. Omar Ishrak,is the former Executive Chairman and Chairman of the Board of Medtronic plc, or Medtronic, a global medical technology company. Dr. Ishrak served as the Chairman and Chief Executive Officer of Medtronic from 2011 to April 2020 and was Executive Chairman until December 2020. Prior to joining Medtronic, he served as President and Chief Executive Officer of GE Healthcare Systems, a provider of medical imaging and diagnostic technology and a division of GE Healthcare, from 2009 to 2011. Dr. Ishrak was President and Chief Executive Officer of GE Healthcare Clinical Systems from 2005 to 2008 and President and Chief Executive Officer of GE Healthcare Ultrasound and BMD from 1995 to 2004.Dr. Ishrak has been a director of Intel Corporation,(1) a multinational corporation and technology company, since 2017, serving as a member of the Audit and Finance Committee and Corporate Governance and Nominating Committee; he was Chairman of its Board from 2020 until 2023. Dr. Ishrak has served as Co-Chairman and lead independent director, as well as a member of the Audit Committee and Nominating and Corporate Governance Committee, of Allurion Technologies, Inc., a weight loss platform combined with gastric balloon, since its merger in 2023 with Compute Health Acquisition Corporation, a special purpose acquisition company, where Dr. Ishrak served as Chairman of the Board of Directors from 2021 until its merger in 2023. Dr. Ishrak is a member of the Board of Trustees of the Asia Society, an educational organization dedicated to promoting mutual understanding and strong partnerships between Asia and the U.S. Since 2021, Dr. Ishrak has been a senior advisor to Blackstone Life Sciences, a segment of Blackstone Inc. that invests in the biopharmaceutical and medical technology industries. Dr. Ishrak was inducted into the American Institute for Medical and Biological Engineering College of Fellows in 2016, elected as a Fellow of King's College London in 2017, inducted into the Bakken Society in 2020, and elected to the National Academy of Engineering in 2020. Dr. Ishrak received his undergraduate degree and doctorate from the University of London, King's College. - S. Omar Ishrak,Medtronic plc，医疗设备公司，董事长兼首席执行官（2011-2020年退休）。GE医疗保健系统是GE医疗保健部门和综合医疗成像和诊断技术提供商。2009-2011年担任总裁兼首席执行官。其他公共董事会成员，生物制药公司Amgen Inc.，医疗保健公司Allurion Technologies Inc.。
- S. Omar Ishrak,is the former Executive Chairman and Chairman of the Board of Medtronic plc, or Medtronic, a global medical technology company. Dr. Ishrak served as the Chairman and Chief Executive Officer of Medtronic from 2011 to April 2020 and was Executive Chairman until December 2020. Prior to joining Medtronic, he served as President and Chief Executive Officer of GE Healthcare Systems, a provider of medical imaging and diagnostic technology and a division of GE Healthcare, from 2009 to 2011. Dr. Ishrak was President and Chief Executive Officer of GE Healthcare Clinical Systems from 2005 to 2008 and President and Chief Executive Officer of GE Healthcare Ultrasound and BMD from 1995 to 2004.Dr. Ishrak has been a director of Intel Corporation,(1) a multinational corporation and technology company, since 2017, serving as a member of the Audit and Finance Committee and Corporate Governance and Nominating Committee; he was Chairman of its Board from 2020 until 2023. Dr. Ishrak has served as Co-Chairman and lead independent director, as well as a member of the Audit Committee and Nominating and Corporate Governance Committee, of Allurion Technologies, Inc., a weight loss platform combined with gastric balloon, since its merger in 2023 with Compute Health Acquisition Corporation, a special purpose acquisition company, where Dr. Ishrak served as Chairman of the Board of Directors from 2021 until its merger in 2023. Dr. Ishrak is a member of the Board of Trustees of the Asia Society, an educational organization dedicated to promoting mutual understanding and strong partnerships between Asia and the U.S. Since 2021, Dr. Ishrak has been a senior advisor to Blackstone Life Sciences, a segment of Blackstone Inc. that invests in the biopharmaceutical and medical technology industries. Dr. Ishrak was inducted into the American Institute for Medical and Biological Engineering College of Fellows in 2016, elected as a Fellow of King's College London in 2017, inducted into the Bakken Society in 2020, and elected to the National Academy of Engineering in 2020. Dr. Ishrak received his undergraduate degree and doctorate from the University of London, King's College.
- Greg C. Garland
-
Greg C. Garland，Phillips 66主席和CEO。2010年被任命为Americas for ConocoPhillips高级副总裁，负责勘探和生产。此前曾于2008-2010年担任雪佛龙菲利浦化学公司（CPChem）总裁和CEO，2000-2008年担任CPChem高级副总裁，负责规划和特殊产品。他还就任于Amgen Inc.和Phillips 66 Partners GP LLC（Phillips 66 Partners LP的普通合伙人）董事会。
Greg C. Garland,was the Executive Chairman of the board of directors of Phillips 66, a diversified energy manufacturing and logistics company, from July 2022 to May 2024, and chaired the Executive Committee. Mr. Garland served as Chairman and Chief Executive Officer of Phillips 66 from 2012 to June 2022. Prior to Phillips 66, Mr. Garland served as Senior Vice President of Exploration and Production, Americas of ConocoPhillips from 2010 to 2012. He was President and Chief Executive Officer of Chevron Phillips Chemical Company (now a joint venture between Phillips 66 and Chevron) from 2008 to 2010 and Senior Vice President, Planning and Specialty Products from 2000 to 2008. Mr. Garland served in various positions at Phillips Petroleum Company from 1980 to 2000. Mr. Garland received an undergraduate degree in Chemical Engineering from Texas A&M University.Mr. Garland is a member of the Engineering Advisory Council for Texas A&M University. He is a member of the Board of Visitors, and an Executive Committee Member of The University of Texas MD Anderson Cancer Center, a leading cancer research and treatment institution. He is a founding member of Houston's CEO Against Cancer. Mr. Garland serves as Vice Chairman of the Barbara Bush Literacy Foundation. - Greg C. Garland，Phillips 66主席和CEO。2010年被任命为Americas for ConocoPhillips高级副总裁，负责勘探和生产。此前曾于2008-2010年担任雪佛龙菲利浦化学公司（CPChem）总裁和CEO，2000-2008年担任CPChem高级副总裁，负责规划和特殊产品。他还就任于Amgen Inc.和Phillips 66 Partners GP LLC（Phillips 66 Partners LP的普通合伙人）董事会。
- Greg C. Garland,was the Executive Chairman of the board of directors of Phillips 66, a diversified energy manufacturing and logistics company, from July 2022 to May 2024, and chaired the Executive Committee. Mr. Garland served as Chairman and Chief Executive Officer of Phillips 66 from 2012 to June 2022. Prior to Phillips 66, Mr. Garland served as Senior Vice President of Exploration and Production, Americas of ConocoPhillips from 2010 to 2012. He was President and Chief Executive Officer of Chevron Phillips Chemical Company (now a joint venture between Phillips 66 and Chevron) from 2008 to 2010 and Senior Vice President, Planning and Specialty Products from 2000 to 2008. Mr. Garland served in various positions at Phillips Petroleum Company from 1980 to 2000. Mr. Garland received an undergraduate degree in Chemical Engineering from Texas A&M University.Mr. Garland is a member of the Engineering Advisory Council for Texas A&M University. He is a member of the Board of Visitors, and an Executive Committee Member of The University of Texas MD Anderson Cancer Center, a leading cancer research and treatment institution. He is a founding member of Houston's CEO Against Cancer. Mr. Garland serves as Vice Chairman of the Barbara Bush Literacy Foundation.
- Tyler E. Jacks
-
Tyler E. Jacks， 1992年加入麻省理工学院，现任戴维H科赫生物学教授和戴维H科赫研究所综合癌症研究主任，该研究所汇集了生物学家和工程师。自2002年成为霍华德休斯医学研究所（一家非盈利的医疗研究组织）调查员；自2009年5月开始担任赛默飞世尔科技公司（一家生命科学供应公司）董事并担任财务委员会、科技委员会和科技顾问董事会成员。2006年成立T2生物系统公司（一家私人控股生物制药公司）；自2007年开始担任多个科技顾问董事，包括Epizyme公司（一家私人控股生物制药公司）；自2001年开始担任乐骋制药公司（一家癌症治疗公司）董事。2011年10月被任命为国际癌症顾问委员会成员，为国际癌症研究所在国际癌症计划上提供建议和帮助。从2001年到2008年担任麻省理工大学癌症研究中心董事并获得多项荣誉，包括癌症研究保罗标志奖和由美国协会颁发的癌症研究杰出成就奖。2009年他被选为美国国家科学院以及美国医学研究所成员。
Tyler E. Jacks,joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology, a position he has held since 2007, and founding director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, having served as director from 2007 to 2021. Since 2021, Dr. Jacks has served as President and director of Break Through Cancer, a foundation bringing together multidisciplinary cancer research teams selected from across five participating institutions.(1) Dr. Jacks was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, from 1994 until 2021.Dr. Jacks has been a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since 2009, serving as the Chair of its Science and Technology Committee and as a member of its Strategy and Finance Committee and its scientific advisory board. In 2006, he co-founded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks served on the scientific advisory boards of SQZ Biotechnologies Company, a biotechnology company, from 2015 until 2023, and Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc., a privately held biopharmaceutical company, and serves as the Chair of its scientific advisory board. Dr. Jacks has served as Vice Chair of the Executive Committee of the Harvard University Board of Overseers since September 2024. In 2011, he was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, and served as Chair until 2016. In 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as co-Chair advising the Cancer MoonshotSM Task Force. Dr. Jacks was a director of MIT's Center for Cancer Research from 2001 to 2007 and received numerous awards including the Paul Marks Prize for Cancer Research and the American Association for Cancer Research Award for Outstanding Achievement. He was elected to the National Academy of Sciences as well as the National Academy of Medicine in 2009 and received the MIT Killian Faculty Achievement Award in 2015. Dr. Jacks received an undergraduate degree from Harvard University and his doctorate from the University of California, San Francisco. - Tyler E. Jacks， 1992年加入麻省理工学院，现任戴维H科赫生物学教授和戴维H科赫研究所综合癌症研究主任，该研究所汇集了生物学家和工程师。自2002年成为霍华德休斯医学研究所（一家非盈利的医疗研究组织）调查员；自2009年5月开始担任赛默飞世尔科技公司（一家生命科学供应公司）董事并担任财务委员会、科技委员会和科技顾问董事会成员。2006年成立T2生物系统公司（一家私人控股生物制药公司）；自2007年开始担任多个科技顾问董事，包括Epizyme公司（一家私人控股生物制药公司）；自2001年开始担任乐骋制药公司（一家癌症治疗公司）董事。2011年10月被任命为国际癌症顾问委员会成员，为国际癌症研究所在国际癌症计划上提供建议和帮助。从2001年到2008年担任麻省理工大学癌症研究中心董事并获得多项荣誉，包括癌症研究保罗标志奖和由美国协会颁发的癌症研究杰出成就奖。2009年他被选为美国国家科学院以及美国医学研究所成员。
- Tyler E. Jacks,joined the faculty of Massachusetts Institute of Technology, or MIT, in 1992 and is currently the David H. Koch Professor of Biology, a position he has held since 2007, and founding director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis and treatment of cancer, having served as director from 2007 to 2021. Since 2021, Dr. Jacks has served as President and director of Break Through Cancer, a foundation bringing together multidisciplinary cancer research teams selected from across five participating institutions.(1) Dr. Jacks was an investigator with the Howard Hughes Medical Institute, a nonprofit medical research organization, from 1994 until 2021.Dr. Jacks has been a director of Thermo Fisher Scientific, Inc., a life sciences supply company, since 2009, serving as the Chair of its Science and Technology Committee and as a member of its Strategy and Finance Committee and its scientific advisory board. In 2006, he co-founded T2 Biosystems, Inc., a biotechnology company, and served on its scientific advisory board until 2013. Dr. Jacks served on the scientific advisory boards of SQZ Biotechnologies Company, a biotechnology company, from 2015 until 2023, and Aveo Pharmaceuticals Inc., a biopharmaceutical company, from 2001 until 2013. In 2015, Dr. Jacks founded Dragonfly Therapeutics, Inc., a privately held biopharmaceutical company, and serves as the Chair of its scientific advisory board. Dr. Jacks has served as Vice Chair of the Executive Committee of the Harvard University Board of Overseers since September 2024. In 2011, he was appointed to the National Cancer Advisory Board, which advises and assists the Director of the National Cancer Institute with respect to the National Cancer Program, and served as Chair until 2016. In 2016, Dr. Jacks was named to a blue ribbon panel of scientists and advisors established as a working group of the National Cancer Advisory Board and served as co-Chair advising the Cancer MoonshotSM Task Force. Dr. Jacks was a director of MIT's Center for Cancer Research from 2001 to 2007 and received numerous awards including the Paul Marks Prize for Cancer Research and the American Association for Cancer Research Award for Outstanding Achievement. He was elected to the National Academy of Sciences as well as the National Academy of Medicine in 2009 and received the MIT Killian Faculty Achievement Award in 2015. Dr. Jacks received an undergraduate degree from Harvard University and his doctorate from the University of California, San Francisco.
- Michael V. Drake
-
Michael V. Drake，自2022年8月起担任董事。自2020年以来，德雷克博士一直担任加州大学校长，该大学由10个校区、5个医疗中心和3个国家附属实验室组成，为超过28万名学生提供服务，并雇用了23万名教职员工。德雷克博士此前曾于2014年至2020年担任俄亥俄州立大学校长。他曾于2005年至2014年担任加州大学欧文分校眼科（医学院）和教育（教育学院）校长和特聘教授，并于2000年至2005年担任加州大学系统卫生事务副总裁。在此之前，德雷克博士自1979年起在加州大学旧金山医学院担任各种职务，并于1998年至2005年担任Steven P. Shearing眼科教授，并于1998年至2000年担任招生和校外学术项目高级副院长。德雷克博士在斯坦福大学获得本科学位，在加州大学旧金山分校获得医学博士学位。
Michael V. Drake,has served as director since 2022. Dr. Drake has been President of the University of California, a system of 10 campuses, five medical centers, and three nationally affiliated labs since 2020.(1) Dr. Drake previously served as President of The Ohio State University from 2014 to 2020. He was Chancellor and Distinguished Professor of Ophthalmology (School of Medicine) and Education (School of Education) of the University of California, Irvine, from 2005 to 2014, and served as Vice President for Health Affairs for the University of California system from 2000 to 2005. Prior to this, Dr. Drake was on the faculty of the University of California, San Francisco School of Medicine in various roles from 1979, and was the Steven P. Shearing Professor of Ophthalmology from 1998 to 2005 and Senior Associate Dean for Admissions and Extramural Academic Programs from 1998 to 2000. Dr. Drake received his undergraduate degree from Stanford University and his medical doctorate from the University of California, San Francisco. - Michael V. Drake，自2022年8月起担任董事。自2020年以来，德雷克博士一直担任加州大学校长，该大学由10个校区、5个医疗中心和3个国家附属实验室组成，为超过28万名学生提供服务，并雇用了23万名教职员工。德雷克博士此前曾于2014年至2020年担任俄亥俄州立大学校长。他曾于2005年至2014年担任加州大学欧文分校眼科（医学院）和教育（教育学院）校长和特聘教授，并于2000年至2005年担任加州大学系统卫生事务副总裁。在此之前，德雷克博士自1979年起在加州大学旧金山医学院担任各种职务，并于1998年至2005年担任Steven P. Shearing眼科教授，并于1998年至2000年担任招生和校外学术项目高级副院长。德雷克博士在斯坦福大学获得本科学位，在加州大学旧金山分校获得医学博士学位。
- Michael V. Drake,has served as director since 2022. Dr. Drake has been President of the University of California, a system of 10 campuses, five medical centers, and three nationally affiliated labs since 2020.(1) Dr. Drake previously served as President of The Ohio State University from 2014 to 2020. He was Chancellor and Distinguished Professor of Ophthalmology (School of Medicine) and Education (School of Education) of the University of California, Irvine, from 2005 to 2014, and served as Vice President for Health Affairs for the University of California system from 2000 to 2005. Prior to this, Dr. Drake was on the faculty of the University of California, San Francisco School of Medicine in various roles from 1979, and was the Steven P. Shearing Professor of Ophthalmology from 1998 to 2005 and Senior Associate Dean for Admissions and Extramural Academic Programs from 1998 to 2000. Dr. Drake received his undergraduate degree from Stanford University and his medical doctorate from the University of California, San Francisco.
高管简历
中英对照 | 中文 | 英文- Robert A. Bradway
Robert A. Bradway自2011年以来一直担任安进公司（Amgen Inc.）的董事，自2013年起担任董事会主席。自2010年起，Bradway先生担任安进公司的总裁，并于2012年起担任首席执行官。从2010年至2012年，Bradway先生担任安进公司的首席运营官。他于2006年加入安进公司，担任运营策略副总裁，并在2007年至2010年期间担任执行副总裁及首席财务官。在加入安进公司之前，他在伦敦摩根士丹利银行担任董事总经理，自2001年起负责该公司在欧洲的银行业务和公司融资活动。自2016年起，Bradway先生一直担任波音公司的董事，并担任财务委员会主席及治理与公共政策委员会的成员。他自2014年以来一直在南加州大学董事会的信任委员会中任职。Bradway先生拥有安普华兹学院的生物学学士学位和哈佛商学院工商管理硕士学位。
Robert A. Bradway,has served as director since 2011 and Chairman of the Board since 2013. Mr. Bradway has been President since 2010 and Chief Executive Officer since 2012. From 2010 to 2012, Mr. Bradway served as Chief Operating Officer. Mr. Bradway joined Amgen in 2006 as Vice President, Operations Strategy and served as Executive Vice President and Chief Financial Officer from 2007 to 2010. Prior to joining Amgen, he was a Managing Director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm's banking department and corporate finance activities in Europe.Mr. Bradway has been a director of The Boeing Company, an aerospace company and manufacturer of commercial airplanes and defense, space and securities systems, since 2016, serving as the Chair of the Governance and Public Policy Committee and a member of the Compensation Committee. He previously served as the Chair of the Finance Committee of Boeing from 2021 to 2024. Mr. Bradway has served on the board of trustees of USC since 2014. Mr. Bradway holds a bachelor's degree in biology from Amherst College and a master's degree in business administration from Harvard Business School.- Robert A. Bradway自2011年以来一直担任安进公司（Amgen Inc.）的董事，自2013年起担任董事会主席。自2010年起，Bradway先生担任安进公司的总裁，并于2012年起担任首席执行官。从2010年至2012年，Bradway先生担任安进公司的首席运营官。他于2006年加入安进公司，担任运营策略副总裁，并在2007年至2010年期间担任执行副总裁及首席财务官。在加入安进公司之前，他在伦敦摩根士丹利银行担任董事总经理，自2001年起负责该公司在欧洲的银行业务和公司融资活动。自2016年起，Bradway先生一直担任波音公司的董事，并担任财务委员会主席及治理与公共政策委员会的成员。他自2014年以来一直在南加州大学董事会的信任委员会中任职。Bradway先生拥有安普华兹学院的生物学学士学位和哈佛商学院工商管理硕士学位。
- Robert A. Bradway,has served as director since 2011 and Chairman of the Board since 2013. Mr. Bradway has been President since 2010 and Chief Executive Officer since 2012. From 2010 to 2012, Mr. Bradway served as Chief Operating Officer. Mr. Bradway joined Amgen in 2006 as Vice President, Operations Strategy and served as Executive Vice President and Chief Financial Officer from 2007 to 2010. Prior to joining Amgen, he was a Managing Director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm's banking department and corporate finance activities in Europe.Mr. Bradway has been a director of The Boeing Company, an aerospace company and manufacturer of commercial airplanes and defense, space and securities systems, since 2016, serving as the Chair of the Governance and Public Policy Committee and a member of the Compensation Committee. He previously served as the Chair of the Finance Committee of Boeing from 2021 to 2024. Mr. Bradway has served on the board of trustees of USC since 2014. Mr. Bradway holds a bachelor's degree in biology from Amherst College and a master's degree in business administration from Harvard Business School.
- James Bradner
James Bradner，于2023年12月成为研发执行副总裁兼首席科学官。在加入公司之前，从2022年到2023年，他是Dana-Farber癌症研究所的临床医生。从2016年到2022年，他担任诺华生物医学研究所总裁，在那里他是诺华公司执行委员会的成员。Bradner博士曾在哈佛医学院任职。
James Bradner,became Executive Vice President, Research and Development, in 2023 and also served as the Company's Chief Scientific Officer from 2023 through December 2024. Prior to joining the Company, from 2022 to 2023, Dr. Bradner was a clinician at the Dana-Farber Cancer Institute, a comprehensive cancer treatment and research institution, and a principal teaching affiliate at Harvard Medical School. From 2016 to 2022, Dr. Bradner served as President of the Novartis Institutes for BioMedical Research, the research and early development organizational unit of Novartis AG, where he was a member of the Executive Committee. Dr. Bradner previously served on the faculty at Harvard Medical School.- James Bradner，于2023年12月成为研发执行副总裁兼首席科学官。在加入公司之前，从2022年到2023年，他是Dana-Farber癌症研究所的临床医生。从2016年到2022年，他担任诺华生物医学研究所总裁，在那里他是诺华公司执行委员会的成员。Bradner博士曾在哈佛医学院任职。
- James Bradner,became Executive Vice President, Research and Development, in 2023 and also served as the Company's Chief Scientific Officer from 2023 through December 2024. Prior to joining the Company, from 2022 to 2023, Dr. Bradner was a clinician at the Dana-Farber Cancer Institute, a comprehensive cancer treatment and research institution, and a principal teaching affiliate at Harvard Medical School. From 2016 to 2022, Dr. Bradner served as President of the Novartis Institutes for BioMedical Research, the research and early development organizational unit of Novartis AG, where he was a member of the Executive Committee. Dr. Bradner previously served on the faculty at Harvard Medical School.
- Esteban Santos
Esteban Santos，于2016年7月成为执行副总裁，负责运营。他于2007年加入公司，担任执行主管，负责制造技术。2008年10月至2013年5月，他曾担任公司的多种副总裁职务，负责工程、制造、现场操作和药物产品。2013年5月至2016年7月，他曾担任高级副总裁，负责制造。加入公司之前，他曾担任站点总裁，负责J&J公司的波多黎各Cordis运营。任职J&J公司之前，他曾担任GE公司的工业和交通运输企业的一些管理职务。
Esteban Santos,became Executive Vice President, Operations, in 2016. Mr. Santos joined the Company in 2007 as Executive Director, Manufacturing Technologies. From 2013 to 2016, Mr. Santos was Senior Vice President, Manufacturing. From 2008 to 2013, Mr. Santos held a number of Vice President roles at the Company in engineering, manufacturing, site operations and drug product. Prior to joining the Company, Mr. Santos served as Site General Manager of Johnson & Johnson's (J&J) Cordis operation in Puerto Rico. Prior to J&J, Mr. Santos held several management positions in GE's industrial and transportation businesses.- Esteban Santos，于2016年7月成为执行副总裁，负责运营。他于2007年加入公司，担任执行主管，负责制造技术。2008年10月至2013年5月，他曾担任公司的多种副总裁职务，负责工程、制造、现场操作和药物产品。2013年5月至2016年7月，他曾担任高级副总裁，负责制造。加入公司之前，他曾担任站点总裁，负责J&J公司的波多黎各Cordis运营。任职J&J公司之前，他曾担任GE公司的工业和交通运输企业的一些管理职务。
- Esteban Santos,became Executive Vice President, Operations, in 2016. Mr. Santos joined the Company in 2007 as Executive Director, Manufacturing Technologies. From 2013 to 2016, Mr. Santos was Senior Vice President, Manufacturing. From 2008 to 2013, Mr. Santos held a number of Vice President roles at the Company in engineering, manufacturing, site operations and drug product. Prior to joining the Company, Mr. Santos served as Site General Manager of Johnson & Johnson's (J&J) Cordis operation in Puerto Rico. Prior to J&J, Mr. Santos held several management positions in GE's industrial and transportation businesses.
- Murdo Gordon
Murdo Gordon，于2018年成为全球商业运营执行副总裁。在加入公司之前，他于2016年至2018年担任BMS（制药公司）的首席商务官。从2015年到2016年，他担任BMS的全球市场主管。在此之前，他在BMS担任各种领导职务超过25年。
Murdo Gordon,became Executive Vice President, Global Commercial Operations, in 2018. Prior to joining the Company, Mr. Gordon was Chief Commercial Officer at Bristol-Myers Squibb Company (BMS), a pharmaceutical company, from 2016 to 2018. Mr. Gordon served as Head of Worldwide Markets at BMS from 2015 to 2016. Prior to that, Mr. Gordon served in a variety of leadership roles at BMS for more than 25 years.- Murdo Gordon，于2018年成为全球商业运营执行副总裁。在加入公司之前，他于2016年至2018年担任BMS（制药公司）的首席商务官。从2015年到2016年，他担任BMS的全球市场主管。在此之前，他在BMS担任各种领导职务超过25年。
- Murdo Gordon,became Executive Vice President, Global Commercial Operations, in 2018. Prior to joining the Company, Mr. Gordon was Chief Commercial Officer at Bristol-Myers Squibb Company (BMS), a pharmaceutical company, from 2016 to 2018. Mr. Gordon served as Head of Worldwide Markets at BMS from 2015 to 2016. Prior to that, Mr. Gordon served in a variety of leadership roles at BMS for more than 25 years.
- Peter H. Griffith
Peter H. Griffith于2020年成为执行副总裁兼首席财务官。格里菲斯先生于2019年加入公司，担任财务执行副总裁。 在加入安进公司之前，格里菲斯先生曾是舍伍德峡谷集团有限公司的总裁。 从1997年至2019年，格里菲斯先生曾是安永会计师事务所（EY）的合伙人，曾任安永会计师事务所（Ernst＆Young）的高级领导职务，最后一个职位是企业发展全球副主席。 在加入安永之前，格里菲斯先生曾担任Wedbush Securities Inc.的董事总经理兼投资银行部主管。
Peter H. Griffith,became Executive Vice President and Chief Financial Officer in 2020. Mr. Griffith joined the Company in 2019 as Executive Vice President, Finance. Prior to joining Amgen, Mr. Griffith was President of Sherwood Canyon Group, LLC, a private equity firm. From 1997 to 2019, Mr. Griffith was a partner at EY, an accounting and professional services firm, and served in a variety of senior leadership roles, with his last position being Global Vice Chair, Corporate Development. Prior to EY, Mr. Griffith was a Managing Director and head of the investment banking division of Wedbush Securities Inc.- Peter H. Griffith于2020年成为执行副总裁兼首席财务官。格里菲斯先生于2019年加入公司，担任财务执行副总裁。 在加入安进公司之前，格里菲斯先生曾是舍伍德峡谷集团有限公司的总裁。 从1997年至2019年，格里菲斯先生曾是安永会计师事务所（EY）的合伙人，曾任安永会计师事务所（Ernst＆Young）的高级领导职务，最后一个职位是企业发展全球副主席。 在加入安永之前，格里菲斯先生曾担任Wedbush Securities Inc.的董事总经理兼投资银行部主管。
- Peter H. Griffith,became Executive Vice President and Chief Financial Officer in 2020. Mr. Griffith joined the Company in 2019 as Executive Vice President, Finance. Prior to joining Amgen, Mr. Griffith was President of Sherwood Canyon Group, LLC, a private equity firm. From 1997 to 2019, Mr. Griffith was a partner at EY, an accounting and professional services firm, and served in a variety of senior leadership roles, with his last position being Global Vice Chair, Corporate Development. Prior to EY, Mr. Griffith was a Managing Director and head of the investment banking division of Wedbush Securities Inc.
- David M. Reese
David M. Reese于2018年成为研发部执行副总裁。Reese博士于2005年加入公司，在开发，医学和发现研究领域担任领导职务。 Reese博士于2017年至2018年担任转化科学与肿瘤学高级副总裁，并于2015年至2017年担任转化科学高级副总裁。在加入Amgen之前，Reese博士自2001年以来担任乳腺癌国际研究小组临床研究总监。 直到2003年，他还是2003年至2005年间非营利性学术临床研究组织Translational Oncology Research International的共同创始人，总裁兼首席医学官。Reese博士曾在加利福尼亚大学洛杉矶分校任教， 加利福尼亚大学旧金山分校。
David M. Reese,became the Company's inaugural Executive Vice President and Chief Technology Officer in December 2023, responsible for accelerating the Amgen Inc. e of technology and artificial intelligence across the organization. From 2018 to December 2023, Dr. Reese served as Executive Vice President, Research and Development. Dr. Reese joined the Company in 2005 and has held leadership roles in development, translational, and medical sciences, and discovery research, including as Senior Vice President, Translational Sciences and Oncology, from 2017 to 2018. Prior to joining Amgen, Dr. Reese was a cofounder, president, and chief medical officer of Translational Oncology Research International, a not-for-profit academic clinical research organization, and director of Clinical Research at the Breast Cancer International Research Group. Dr. Reese previously served on the faculty at the University of California, Los Angeles and the University of California, San Francisco.- David M. Reese于2018年成为研发部执行副总裁。Reese博士于2005年加入公司，在开发，医学和发现研究领域担任领导职务。 Reese博士于2017年至2018年担任转化科学与肿瘤学高级副总裁，并于2015年至2017年担任转化科学高级副总裁。在加入Amgen之前，Reese博士自2001年以来担任乳腺癌国际研究小组临床研究总监。 直到2003年，他还是2003年至2005年间非营利性学术临床研究组织Translational Oncology Research International的共同创始人，总裁兼首席医学官。Reese博士曾在加利福尼亚大学洛杉矶分校任教， 加利福尼亚大学旧金山分校。
- David M. Reese,became the Company's inaugural Executive Vice President and Chief Technology Officer in December 2023, responsible for accelerating the Amgen Inc. e of technology and artificial intelligence across the organization. From 2018 to December 2023, Dr. Reese served as Executive Vice President, Research and Development. Dr. Reese joined the Company in 2005 and has held leadership roles in development, translational, and medical sciences, and discovery research, including as Senior Vice President, Translational Sciences and Oncology, from 2017 to 2018. Prior to joining Amgen, Dr. Reese was a cofounder, president, and chief medical officer of Translational Oncology Research International, a not-for-profit academic clinical research organization, and director of Clinical Research at the Breast Cancer International Research Group. Dr. Reese previously served on the faculty at the University of California, Los Angeles and the University of California, San Francisco.
- Nancy A. Grygiel
Nancy A. Grygiel于2020年成为高级副总裁兼首席合规官。Grygiel女士于2015年加入菲利普莫里斯国际公司。从2016年到2020年，Grygiel女士担任合规部副总裁。在加入安进之前，Grygiel女士在2011年至2015年期间担任Allergan，Inc.公司企业与国际合规副总裁。在加入Allergan之前，Grygiel女士曾在Mylan Pharmaceuticals，Inc.担任多个管理职位。
Nancy A. Grygiel,became Senior Vice President and Chief Compliance Officer in 2020. Ms. Grygiel joined the Company in 2015. From 2016 to 2020, Ms. Grygiel was Vice President, Compliance. Prior to joining Amgen, from 2011 to 2015, Ms. Grygiel served as Vice President, Compliance, Corporate & International, at Allergan, Inc. (Allergan). Prior to Allergan, Ms. Grygiel held several management positions at Mylan Pharmaceuticals, Inc.- Nancy A. Grygiel于2020年成为高级副总裁兼首席合规官。Grygiel女士于2015年加入菲利普莫里斯国际公司。从2016年到2020年，Grygiel女士担任合规部副总裁。在加入安进之前，Grygiel女士在2011年至2015年期间担任Allergan，Inc.公司企业与国际合规副总裁。在加入Allergan之前，Grygiel女士曾在Mylan Pharmaceuticals，Inc.担任多个管理职位。
- Nancy A. Grygiel,became Senior Vice President and Chief Compliance Officer in 2020. Ms. Grygiel joined the Company in 2015. From 2016 to 2020, Ms. Grygiel was Vice President, Compliance. Prior to joining Amgen, from 2011 to 2015, Ms. Grygiel served as Vice President, Compliance, Corporate & International, at Allergan, Inc. (Allergan). Prior to Allergan, Ms. Grygiel held several management positions at Mylan Pharmaceuticals, Inc.
- Rachna Khosla
Rachna Khosla，2021，成为业务发展高级副总裁。Khosla女士于2013年加入Amgen Inc.，担任Amgen Inc.发展总监。从2016到2018 Khosla女士是执行董事，业务发展，从2018到2021是副总裁，业务发展。在加入Amgen Inc.之前，Khosla女士是拉扎德有限公司的董事。拉扎德负责医疗并购。在Lazard之前，Khosla女士曾在瑞士信贷集团、赛诺菲-安万特、安万特资本、摩根大通和所罗门兄弟公司担任过多个职务。
Rachna Khosla,became Senior Vice President, Business Development, in 2021. Ms. Khosla joined the Company in 2013 as Corporate Development Director. From 2018 to 2021, Ms. Khosla was Vice President, Business Development, and from 2016 to 2018, was Executive Director, Business Development. Prior to joining the Company, Ms. Khosla was a Director at Lazard Ltd. (Lazard) responsible for healthcare mergers and acquisitions. Prior to Lazard, Ms. Khosla held various roles in investment banking (mergers and acquisitions) and corporate venture capital at Credit Suisse Group AG, Sanofi Aventis, Aventis Capital, J.P. Morgan Chase & Co., and Salomon Brothers, Inc.- Rachna Khosla，2021，成为业务发展高级副总裁。Khosla女士于2013年加入Amgen Inc.，担任Amgen Inc.发展总监。从2016到2018 Khosla女士是执行董事，业务发展，从2018到2021是副总裁，业务发展。在加入Amgen Inc.之前，Khosla女士是拉扎德有限公司的董事。拉扎德负责医疗并购。在Lazard之前，Khosla女士曾在瑞士信贷集团、赛诺菲-安万特、安万特资本、摩根大通和所罗门兄弟公司担任过多个职务。
- Rachna Khosla,became Senior Vice President, Business Development, in 2021. Ms. Khosla joined the Company in 2013 as Corporate Development Director. From 2018 to 2021, Ms. Khosla was Vice President, Business Development, and from 2016 to 2018, was Executive Director, Business Development. Prior to joining the Company, Ms. Khosla was a Director at Lazard Ltd. (Lazard) responsible for healthcare mergers and acquisitions. Prior to Lazard, Ms. Khosla held various roles in investment banking (mergers and acquisitions) and corporate venture capital at Credit Suisse Group AG, Sanofi Aventis, Aventis Capital, J.P. Morgan Chase & Co., and Salomon Brothers, Inc.
- Derek Miller
Derek Miller于2022年成为人力资源高级副总裁。Miller先生于2003年加入公司，担任过人力资源领导职务，为公司的每一项主要业务职能提供支持。从2020年到2022年，Miller先生担任全球总报酬副总裁，从2018年到2020年，担任人力资源副总裁。2015年至2018年，Miller先生担任人力资源执行主任。在2015年之前，Miller先生曾在人力资源组织担任高级经理，之后晋升为人力资源总监，然后晋升为战略总监。
Derek Miller,became Senior Vice President, Human Resources, in 2022. Mr. Miller joined the Company in 2003 and has held human resources leadership roles supporting each of the Company's major business functions. From 2020 to 2022, Mr. Miller was Vice President, Global Total Rewards, and from 2018 to 2020, was Vice President, Human Resources. From 2015 to 2018, Mr. Miller was an Executive Director, Human Resources. Prior to 2015, Mr. Miller served as a Senior Manager in the Human Resources organization, before his promotion to Director, Human Resources, and then to Strategy Director.- Derek Miller于2022年成为人力资源高级副总裁。Miller先生于2003年加入公司，担任过人力资源领导职务，为公司的每一项主要业务职能提供支持。从2020年到2022年，Miller先生担任全球总报酬副总裁，从2018年到2020年，担任人力资源副总裁。2015年至2018年，Miller先生担任人力资源执行主任。在2015年之前，Miller先生曾在人力资源组织担任高级经理，之后晋升为人力资源总监，然后晋升为战略总监。
- Derek Miller,became Senior Vice President, Human Resources, in 2022. Mr. Miller joined the Company in 2003 and has held human resources leadership roles supporting each of the Company's major business functions. From 2020 to 2022, Mr. Miller was Vice President, Global Total Rewards, and from 2018 to 2020, was Vice President, Human Resources. From 2015 to 2018, Mr. Miller was an Executive Director, Human Resources. Prior to 2015, Mr. Miller served as a Senior Manager in the Human Resources organization, before his promotion to Director, Human Resources, and then to Strategy Director.
- Matthew C. Busch
Matthew C. Busch，自2021年8月起担任Amgen Inc.的财务副总裁。从2020年到2021年8月，Busch先生担任财务执行董事，从2017年到2020年担任会计执行董事。从2004年到2017年，Busch先生在公司担任各种职务。他是一名注册会计师，并获得Brigham Young University会计硕士学位和会计学学士学位。
Matthew C. Busch,has served as the Amgen Inc.'s Vice President, Finance since August 2021. From 2020 until August 2021, Mr. Busch served as Executive Director, Finance and, from 2017 until 2020, as Executive Director, Accounting. From 2004 until 2017, Mr. Busch progressed through various positions of increasing responsibility at the Company. He is a Certified Public Accountant and received his Masters of Accountancy degree and Bachelors of Science in Accounting from Brigham Young University.- Matthew C. Busch，自2021年8月起担任Amgen Inc.的财务副总裁。从2020年到2021年8月，Busch先生担任财务执行董事，从2017年到2020年担任会计执行董事。从2004年到2017年，Busch先生在公司担任各种职务。他是一名注册会计师，并获得Brigham Young University会计硕士学位和会计学学士学位。
- Matthew C. Busch,has served as the Amgen Inc.'s Vice President, Finance since August 2021. From 2020 until August 2021, Mr. Busch served as Executive Director, Finance and, from 2017 until 2020, as Executive Director, Accounting. From 2004 until 2017, Mr. Busch progressed through various positions of increasing responsibility at the Company. He is a Certified Public Accountant and received his Masters of Accountancy degree and Bachelors of Science in Accounting from Brigham Young University.
- Jonathan P. Graham
Jonathan P. Graham于2019年起担任执行副总裁兼总法律顾问和秘书。Graham先生于2015年加入公司。2015年至2019年，Graham先生担任高级副总裁、总法律顾问和秘书。在2006年至2015年加入Amgen之前，Graham先生是Danaher Corporation的高级副总裁兼总法律顾问。2004年至2006年，Graham先生在通用电气公司（GE）担任诉讼和法律政策副总裁。在加入GE之前，Graham是Williams & Connolly LLP的合伙人。
Jonathan P. Graham,became Executive Vice President and General Counsel and Secretary in 2019. Mr. Graham joined the Company in 2015. From 2015 to 2019, Mr. Graham was Senior Vice President, General Counsel and Secretary. Prior to joining Amgen, from 2006 to 2015, Mr. Graham was Senior Vice President and General Counsel at Danaher Corporation. From 2004 to 2006, Mr. Graham was Vice President, Litigation and Legal Policy, at General Electric Company (GE). Prior to GE, Mr. Graham was a partner at Williams & Connolly LLP.- Jonathan P. Graham于2019年起担任执行副总裁兼总法律顾问和秘书。Graham先生于2015年加入公司。2015年至2019年，Graham先生担任高级副总裁、总法律顾问和秘书。在2006年至2015年加入Amgen之前，Graham先生是Danaher Corporation的高级副总裁兼总法律顾问。2004年至2006年，Graham先生在通用电气公司（GE）担任诉讼和法律政策副总裁。在加入GE之前，Graham是Williams & Connolly LLP的合伙人。
- Jonathan P. Graham,became Executive Vice President and General Counsel and Secretary in 2019. Mr. Graham joined the Company in 2015. From 2015 to 2019, Mr. Graham was Senior Vice President, General Counsel and Secretary. Prior to joining Amgen, from 2006 to 2015, Mr. Graham was Senior Vice President and General Counsel at Danaher Corporation. From 2004 to 2006, Mr. Graham was Vice President, Litigation and Legal Policy, at General Electric Company (GE). Prior to GE, Mr. Graham was a partner at Williams & Connolly LLP.